Company intelligence / Profile preview

Advanced Life Science Institute

Kawaguchi, Saitama, Japanalsi-jp.com ↗

Ownership: Private
Development stage: Other

Overview

Advanced Life Science Institute (ALSI) has successfully commercialized multiple diagnostic assays, most notably the HCV Core Antigen ELISA which is used globally for Hepatitis C screening and monitoring. They have also developed several research-use and clinical biomarkers for Alzheimer's disease, including AD7C-NTP, Amyloid-beta, and Tau assays.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Monoclonal antibodyRecombinant proteinBiologic
Industry: Protein Biomarker Diagnostics

Partnerships

Ortho-Clinical DiagnosticsFujirebioSekisui MedicalAbbott

Beyond the preview

Go deeper on Advanced Life Science Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced Life Science Institute.